Venom disintegrin

Venom disintegrins and non-enzymatic integrin-binding toxins, such as C-type lectin-like proteins (snaclecs), are key components found in the venoms of Crotalidae snakes [PubMed: 15661575]. These proteins are characterized by their ability to bind with high affinity and specificity to various integrin receptors on cell surfaces, most notably the alpha-IIb-beta-3 receptor on platelets [UniProt: P0C6A8]. Disintegrins typically utilize a conserved Arg-Gly-Asp (RGD) or similar motif to competitively inhibit the binding of endogenous ligands like fibrinogen, thereby preventing platelet aggregation [NCBI: NBK537027]. Non-enzymatic toxins like snaclecs can also modulate platelet function by binding to receptors such as GPIb or GPVI [PubMed: 21530757]. In clinical medicine, these toxins have served as structural templates for the development of potent antiplatelet drugs, including eptifibatide, which is used to manage acute coronary syndromes [StatPearls: NBK541043]. Furthermore, they are critical antigens in the venoms used to immunize animals for the production of polyvalent antivenoms, such as CroFab [PubMed: 28602707]. Beyond their role in envenomation and hematology, these molecules are researched for their potential to inhibit angiogenesis and tumor metastasis by targeting alpha-v-beta-3 integrins [PubMed: 17403008].

Other names

Snake venom disintegrinsRGD-disintegrinsIntegrin-binding toxinsCrotalid disintegrinsVenom disintegrins and other non-enzymatic integrin-binding toxins from the immunizing crotalid venoms

Venom disintegrins and non-enzymatic toxins act as potent, competitive antagonists or modulators of integrin receptors. Disintegrins specifically target receptors like alpha-IIb-beta-3 and alpha-v-beta-3 by mimicking the RGD recognition motif of extracellular matrix proteins, effectively blocking ligand binding and downstream signaling [PubMed: 15661575, NCBI: NBK537027]. Other non-enzymatic toxins, such as C-type lectin-like proteins, may bind to different sites on integrins or related receptors to either inhibit or inappropriately activate platelet adhesion and aggregation [PubMed: 21530757].